11 terminated. 11 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Terminated 11 |
| Phase 3 | 3 | Terminated 3 |
Follow Chromosome Disorders: new trials by email Literature Review of Chromosome Disorders trials Research Report on Chromosome Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome RAD011, Placebo - Prader-Willi Syndrome | Phase 2 / Phase 3 | Terminated | Radius Pharmaceuticals, Inc. | 4 | 2022-04-13 | 2023-10-19 |
| CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS) CBDV Compound, Placebo - Prader-Willi Syndrome | Phase 2 | Terminated | Eric Hollander | 6 | 2020-11-23 | 2026-05-07 |
| Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome Livoletide, Placebo - Prader-Willi Syndrome, Hyperphagia | Phase 2 / Phase 3 | Terminated | Millendo Therapeutics SAS | 158 | 2019-03-25 | 2021-02-17 |
| A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome Cannabidiol Oral Solution - Prader-Willi Syndrome | Phase 2 | Terminated | Radius Pharmaceuticals, Inc. | 2 | 2018-09-06 | 2023-06-22 |
| Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome Cannabidiol, Placebo - Prader-Willi Syndrome | Phase 2 | Terminated | Radius Pharmaceuticals, Inc. | 7 | 2018-05-09 | 2023-08-01 |
| A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age Placebo, RO5186582 - Down Syndrome | Phase 2 | Terminated | Hoffmann-La Roche | 45 | 2015-10-28 | 2017-07-06 |
| Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label) AFQ056 - Fragile X Syndrome | Phase 2 / Phase 3 | Terminated | Novartis Pharmaceuticals | 119 | 2011-11-01 | 2016-03-24 |
| Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome AFQ056 - Fragile X Syndrome | Phase 2 | Terminated | Novartis Pharmaceuticals | 148 | 2011-08-01 | 2016-05-25 |
| Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome Metyrosine, Placebo - Velo-cardio-facial Syndrome, Psychosis | Phase 2 | Terminated | Bausch Health Americas, Inc. | 2 | 2010-06-01 | 2019-11-22 |
| An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome Arbaclofen - Fragile X Syndrome | Phase 2 | Terminated | Seaside Therapeutics, Inc. | 45 | 2009-11-01 | 2012-12-20 |
| Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial Donepezil hydrochloride (Aricept) - Down Syndrome | Phase 2 | Terminated | Eisai Inc. | 117 | 2008-04-04 | 2021-03-29 |
Prader-Willi Syndrome (5) · Fragile X Syndrome (3) · Down Syndrome (2) · Genetic Diseases, Inborn (2) · DiGeorge Syndrome (1) · Hyperphagia (1) · Psychotic Disorders (1)
Congenital Abnormalities (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Intellectual Disability (10) · Nervous System Diseases (10) · Neurobehavioral Manifestations (10) · Neurologic Manifestations (10) · Genetic Diseases, Inborn (9) · Abnormalities, Multiple (8) · Imprinting Disorders (5) · Nutrition Disorders (5) · Nutritional and Metabolic Diseases (5) · Obesity (5) · Overnutrition (5) · Overweight (5)
Cannabidiol (2) · mavoglurant (2) · Donepezil (1) · alpha-Methyltyrosine (1) · arbaclofen placarbil (1) · cannabidivarin (1) · cyclic des-acyl ghrelin (6-13) (1)
Radius Pharmaceuticals, Inc. (3) · Novartis Pharmaceuticals (2) · Bausch Health Americas, Inc. (1) · Eisai Inc. (1) · Eric Hollander (1) · Hoffmann-La Roche (1) · Millendo Therapeutics SAS (1) · Seaside Therapeutics, Inc. (1)
United States (11) · Australia (3) · France (3) · Italy (3) · Spain (3) · United Kingdom (3) · Belgium (2) · Denmark (2) · Germany (2) · Netherlands (2) · Switzerland (2) · Canada (1) · Israel (1) · Sweden (1)
Ahmed Elkashef, MD (2) · Eric Hollander, MD (1) · Robert J Shprintzen, PhD (1)